0000000000610199

AUTHOR

Nahum Méndez-sánchez

showing 3 related works from this author

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2018

PubMed: 29599078

0301 basic medicineBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.HBsAgPediatricsDelphi TechniqueInfectious Disease TransmissionCHRONIC HBV INFECTION ; NATURAL-HISTORY ; FOLLOW-UP ; HBSAG ; CARRIERS ; AGE ; COUNTRIES ; DISEASE ; ANTIGEN ; COHORTddc:616.07Global Healthmedicine.disease_causeDISEASE0302 clinical medicinePrevalenceHBVChildddc:616Antiviral Agents/therapeutic useeducation.field_of_studyBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Chronic/drug therapy/epidemiology/prevention & control/transmissionGastroenterologyHepatitis B Surface Antigens/bloodHepatitis BCARRIERSHepatitis B10219 Clinic for Gastroenterology and HepatologyChild Preschool030211 gastroenterology & hepatologyViral hepatitisViral loadCOUNTRIESAdultmedicine.medical_specialtyHepatitis B vaccineANTIGENPopulation610 Medicine & healthAntiviral AgentsMass VaccinationHepatology; Gastroenterology03 medical and health sciencesHepatitis B ChronicHBSAGAGESDG 3 - Good Health and Well-beingmedicineHumansCOHORT2715 GastroenterologyPreschooleducationDisease burdenHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryViral VaccinesNATURAL-HISTORYmedicine.diseaseInfectious Disease Transmission VerticalCHRONIC HBV INFECTIONVertical/prevention & control030104 developmental biology2721 HepatologyHuman medicineFOLLOW-UPbusiness
researchProduct

Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study

2017

WOS: 000426979400014

Viremia/epidemiologyPopulation ageingmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDDelphi TechniqueGenotypeVoxilaprevirGenotype Global Health Hepatitis C Eradication Modelling studyMedicina Clínicaddc:616.07Global HealthBioinformatics03 medical and health sciences0302 clinical medicineCost of IllnessEpidemiologyJournal ArticlemedicineGlobal healthPrevalenceHumansViremia030212 general & internal medicineDisease EradicationDisease burdenddc:616HepatologyHepatitis C Chronic/epidemiologybusiness.industryGastroenterologyHepatitis CGlecaprevirHepatitis C Chronicmedicine.diseaseViremia/epidemiology/geneticsPibrentasvirGlobal Health/statistics & numerical dataHCVHEPATITIS C030211 gastroenterology & hepatologyMedicina Critica y de EmergenciaHuman medicinebusinessChronic/epidemiology/genetics/prevention & controlDemography
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct